Compare Costco Wholesale Corporation (COST) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Heron Therapeutics Inc — how do they compare? Costco Wholesale Corporation trades at $943.45 (market cap $422.52B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Costco Wholesale Corporation is far larger — about 6663.3× Heron Therapeutics Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COST | HRTX | |
|---|---|---|
Market Cap | $422.52B | $63.41M |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $1.49 |
52-Week Low | $849.63 | $0.32 |
Enterprise Value | $410.66B | $161.31M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $952.75, up 0.52% with a neutral technical outlook. The stock shows strong fundamentals with revenue growth from $254.5B in 2024 to $275.2B in 2025 and net income reaching $8.1B. Recent March sales surged 11.3% year-over-year to $28.41B. Valuation metrics remain elevated with P/E at 47.93 and P/S at 1.44. Analyst consensus is strongly bullish with 65.5% buy ratings and a $1,120 price target.
The investment case centers on Costco's membership-driven profit engine and consistent execution, though high valuation presents near-term risk. Upside potential exists if the company maintains its premium growth trajectory, while any earnings disappointment could trigger valuation compression. The recent membership fee increase and strong renewal rates support margin expansion prospects.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
